Sign in

CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
820606654
Phone
(650) 331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
Open-market buys, last 90 days
$11,602
in 1 filing
Open-market sales, last 90 days
$117,428
in 4 filings, $104K under 10b5-1 plans

Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 94 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-05-22 Wong Stephanie Director Grant or award · Stock Option (Right to Buy) +19,111 19,111
2025-05-22 Marks Gilbert Lynn Director Grant or award · Stock Option (Right to Buy) +19,111 19,111
2025-05-22 Aziz Kabeer Director Grant or award · Stock Optin (Right to Buy) +19,111 19,111
2025-04-10 Zakrzewski Joseph S Director Grant or award +10,523 145,538
2025-04-10 Aziz Kabeer Director Grant or award +9,705 18,677
2025-04-10 Martin Patricia A. Director Grant or award +3,065 6,231
2025-04-10 Marks Gilbert Lynn Director Grant or award +9,705 41,507
2025-02-26 Chanda Sanjay Chief Development Officer Grant or award +50,250 80,074
2025-02-26 Chanda Sanjay Chief Development Officer Grant or award · Stock Option (right to buy) +100,500 100,500
2025-02-26 Day Lucy Chief Financial Officer Grant or award +46,500 79,170
2025-02-26 Day Lucy Chief Financial Officer Grant or award · Stock Option (right to buy) −93,000 93,000
2025-02-26 Eizen Joshua M See Remarks Grant or award +58,500 175,172
2025-02-26 Eizen Joshua M See Remarks Grant or award · Stock Option (right to buy) +117,000 117,000
2025-02-26 Easom Eric Chief Executive Officer Grant or award +145,250 246,380
2025-02-26 Easom Eric Chief Executive Officer Grant or award · Stock Option (right to buy) +290,500 290,500
2025-02-26 Prior Stephen David Chief Strategy Officer Grant or award +28,000 61,313
2025-02-26 Prior Stephen David Chief Strategy Officer Grant or award · Stock Option (right to buy) +56,000 56,000
2025-01-03 Day Lucy Chief Financial Officer Sale −2,957 $1.34 $4K 32,670
2025-01-03 Chanda Sanjay Chief Development Officer Sale −2,957 $1.34 $4K 29,824
2025-01-03 Prior Stephen David Chief Strategy Officer Sale −2,029 $1.34 $3K 33,313

Page 8 of 10 · 191 trades